The molecular substrates underlying cocaine reinforcement and addiction have been studied for decades, with a primary focus on signaling molecules involved in modulation of neuronal communication. Brain-derived neurotrophic factor (BDNF) is an important signaling molecule involved in neuronal dendrite and spine modulation. Methyl CpG binding protein 2 (MeCP2) binds to the promoter region of BDNF to negatively regulate its expression and cocaine can recruit MeCP2 to alter the expression of genes such as BDNF that are involved in synaptic plasticity. For several decades, BDNF has been implicated in mediating synaptic plasticity associated with cocaine abuse, and most studies report that neurons are the primary source for BDNF production in the brain. The current study assessed the effects of intravenous cocaine self-administration on microglial activation, and MeCP2 and BDNF expression in reward regions of the brain in vivo, as well as determined specific effects of cocaine exposure on MeCP2 and BDNF expression in human primary neurons and microglia. The results from this study highlight a distinct molecular pathway in microglia through which cocaine increases BDNF, including the phosphorylation of MeCP2 its subsequent translocation from the nucleus to the cytosol, which frees the BDNF promoter and permits its transcriptional activation. Results from these studies show for the first time that cocaine self-administration increases microglial activation, and that microglial MeCP2 is a sensitive target of cocaine resulting in increased release of BDNF from microglia, and possibly contributing to cocaine-induced synaptic plasticity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051925PMC
http://dx.doi.org/10.1016/j.nbd.2018.05.017DOI Listing

Publication Analysis

Top Keywords

mecp2 bdnf
12
synaptic plasticity
12
bdnf
11
microglial mecp2
8
bdnf production
8
cocaine
8
cocaine self-administration
8
microglial activation
8
bdnf expression
8
mecp2
7

Similar Publications

Therapeutic effects of CGS21680, a selective A receptor agonist, via BDNF-related pathways in R106W mutation Rett syndrome model.

Biomed Pharmacother

January 2025

College of Veterinary Medicine, Konkuk University, 120, Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. Electronic address:

Rett syndrome (RTT) is a neurological disorder caused by a mutation in the X-linked methyl-CpG binding protein 2 (MECP2), leading to cognitive and motor skill regression. Therapeutic strategies aimed at increasing brain-derived neurotrophic factor (BDNF) levels have been reported; however, BDNF treatment has limitations, including the inability to penetrate the blood-brain barrier, a short half-life, and potential for adverse effects when administered via intrathecal injection, necessitating novel therapeutic approaches. In this study, we focused on the adenosine A receptor (AR), which modulates BDNF and its downstream pathways, and investigated the therapeutic potential of CGS21680, an AR agonist, through in vitro and in vivo studies using R106W RTT model.

View Article and Find Full Text PDF
Article Synopsis
  • Rett syndrome (RTT) is caused by mutations in the MECP2 gene, and while traditional gene therapies face challenges due to toxicity risks, restoring MECP2 levels shows promise in mouse models.
  • The study focuses on site-blocking antisense oligonucleotides (sbASOs) that can prevent repressive miRNA binding to the MECP2 3'UTR, potentially increasing protein levels in patients with RTT.
  • Results show that sbASOs can safely upregulate MECP2 levels in various cell lines and mice, suggesting they could be a viable treatment option for disorders related to MECP2 deficiencies.
View Article and Find Full Text PDF
Article Synopsis
  • Alzheimer's disease is associated with Aβ accumulation, tau hyperphosphorylation, neuroinflammation, and decreased neurotrophic factors, which impair memory and learning.
  • The study involved administering Aβ to rats and then treating them with intranasal oxytocin to assess its effects on memory, neurogenesis, and synaptic plasticity.
  • Results showed that intranasal oxytocin significantly enhanced spatial and working memory while increasing key factors related to synaptic plasticity, neurogenesis, and histone acetylation, suggesting potential therapeutic benefits for Alzheimer's disease.
View Article and Find Full Text PDF

Using Precision Medicine to Disentangle Genotype-Phenotype Relationships in Twins with Rett Syndrome: A Case Report.

Curr Issues Mol Biol

August 2024

Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.

Rett syndrome (RTT) is a paediatric neurodevelopmental disorder spanning four developmental stages. This multi-system disorder offers a unique window to explore genotype-phenotype relationships in a disease model. However, genetic prognosticators of RTT have limited clinical value due to the disorder's heterogeneity on multiple levels.

View Article and Find Full Text PDF

Methyl-CpG-binding protein 2 () is an epigenetic modulator and numerous studies have explored its impact on the central nervous system manifestations. However, little attention has been given to its potential contributions to the peripheral nervous system (PNS). To investigate the regulation of in the PNS on specific central regions, we generated mice with the sensory-neuron-specific deletion of the gene and found the mutant mice had a heightened sensitivity to temperature, which, however, did not affect the sense of motion, social behaviors, and anxiety-like behavior.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!